预约演示
更新于：2025-01-27
Etoposide
依托泊苷
更新于：2025-01-27
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C29H32O13 |
InChIKeyVJJPUSNTGOMMGY-MRVIYFEKSA-N |
CAS号33419-42-0 |
关联
1,530
项与 依托泊苷 相关的临床试验NCT06738368
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) ± Rituximab + Recombinant Erwinia Asparaginase (JZP458; Rylaze®) for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Lymphoma/Leukemia
NCT06692452
A Phase II Study of Tazemetostat in Combination with CHOP for Previously Untreated T Cell Lymphoma
NCT06401330
Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
100 项与 依托泊苷 相关的临床结果
登录后查看更多信息
100 项与 依托泊苷 相关的转化医学
登录后查看更多信息
100 项与 依托泊苷 相关的专利（医药）
登录后查看更多信息
35,091
项与 依托泊苷 相关的文献（医药）2025-03-01PEDIATRIC BLOOD & CANCER
Rhabdoid Tumor of the Kidney and Soft Tissues: Results from National Wilms Tumor Study‐5 and Children's Oncology Group Study AREN0321
Article
作者: Renfro, Lindsay A. ; Daw, Najat C. ; Geller, James I. ; Warwick, Anne B. ; Dome, Jeffrey S. ; Tochner, Zelig ; Paulino, Arnold ; Gow, Kenneth ; Hoffer, Fredric A. ; Gratias, Eric ; Anderson, James R. ; Fernandez, Conrad V. ; Ward, Deborah A. ; Biegel, Jackie ; Ehrlich, Peter F. ; Mullen, Elizabeth A. ; Kalapurakal, John A. ; Huff, Vicki ; Grundy, Paul E. ; Perlman, Elizabeth J.
ABSTRACT:
Purpose:
National Wilms Tumor Study‐5 (NWTS‐5) and AREN0321 evaluated the outcomes of children with rhabdoid tumor of the kidney (RTK) and malignant rhabdoid tumor of soft tissues (MRT).
Patients and Methods:
Eligible patients with RTK were enrolled prospectively on NWTS‐5 (1995–2002) and treated with carboplatin and etoposide alternating with cyclophosphamide (Regimen RTK). Patients with RTK or MRT were enrolled on AREN0321 (2005–2012) and received vincristine, doxorubicin, and cyclophosphamide alternating with carboplatin, cyclophosphamide, and etoposide (Regimens UH‐1 or dose‐reduced Revised UH‐1). We report event‐free survival (EFS) and overall survival (OS) from each study.
Results:
Thirty patients received Regimen RTK on NWTS‐5; on AREN0321, 20 received UH‐1 and 19 received Revised UH‐1. Patient and disease characteristics were statistically similar between studies. Patients on AREN0321 had significantly improved EFS and OS compared to those on NWTS‐5 (4‐year EFS = 23.1% vs. 16.7%; p = 0.020; 4‐year OS = 30.6% vs. 20.0%; p = 0.014), mostly driven by patients with Stage I/II disease (p = 0.05). Median time to an event was 3.6 months on NWTS‐5 compared to 7.2 months on AREN0321. There were no differences in EFS or OS by revised versus original Regimen UH‐1 on AREN0321, or by renal versus extra‐renal primary disease when the studies were pooled.
Conclusions:
The more intensive treatment regimen used on AREN0321 improved EFS and OS overall, a result driven by patients with Stage I/II disease. Despite this improvement, outcomes for patients with rhabdoid tumor remain unsatisfactory and there is a need for novel therapeutic strategies.
2025-03-01BIOORGANIC CHEMISTRY
New series of fluoroquinolone derivatives as potential anticancer Agents: Design, Synthesis, in vitro biological Evaluation, and Topoisomerase II Inhibition
Article
作者: El-Masry, Rana M ; Adly, Mina E ; Salem, Mohamed A ; Taher, Azza T ; Ahmed, Fakher M ; Mahmoud, Ashraf M
A series of fluoroquinolone analogs (II, IIIa-g) derived from Ciprofloxacin hydrazide were designed, and synthesized. The NCI-60 Human Tumor Cell Line Screening assay indicated that compounds II, IIIb, and IIIf are the most potent among the series and were further selected for five-dose evaluation, where they exhibited potent cytotoxicity with mean GI50 values of 3.30, 2.45, and 9.06 µM, respectively, where they reduced the cell proliferation of most of the tested cell lines with IC50 values significantly lower than the reference drug Etoposide. A selectivity study demonstrated the high selective cytotoxicity of IIIf towards cancerous cells over normal mammalian Vero cells, presenting it as a potent and selective antitumor agent. Cell cycle analysis revealed that treatment with II, IIIb, or IIIf induced cell cycle arrest at the G2/M phase in MCF-7 cells. Topoisomerase II enzyme inhibition assay showed that the three tested compounds are potent topo II inhibitors where compound II (IC50 = 51.66 µM) displayed more potent inhibitory activity compared to the well-known topo II inhibitor Etoposide (IC50 = 58.96 µM), while compounds IIIb and IIIf showed comparable activity to the reference drug. Molecular modeling study suggested that the topoisomerase inhibitory activity may be attributed to the binding to the Merbarone binding site and chelation with Mg2+.
2025-03-01INTERNATIONAL JOURNAL OF CANCER
Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post‐hoc analysis of the phase I/III IMpower 133 trial
Article
作者: Pinato, David J. ; Cortellini, Alessio ; Shimokawa, Mototsugu ; Takamori, Shinkichi ; Takada, Kazuki
Abstract:
The potential impact of concomitant medications such as systemic antibiotics, proton pump inhibitors (PPIs), and probiotics in patients with extensive‐stage small cell lung cancer (ES‐SCLC) receiving first‐line chemo‐immunotherapy combinations remains unclear. We ran a post hoc analysis of the IMpower133 phase I/III trial, which randomized patients with ES‐SCLC to receive carboplatin/etoposide with either atezolizumab or placebo for 4 cycles, followed by maintenance therapy. We included any systemic antibiotic/probiotic exposure within 42 days prior to treatment initiation and any PPIs treatment within 30 days prior to treatment initiation. We explored the potential prognostic impact of antibiotics, PPIs and probiotics across the atezolizumab/chemotherapy and placebo/chemotherapy arms including the multivariable interaction term between the treatment modality and antibiotics/PPIs/probiotics. The analysis included 198 patients in the atezolizumab/chemotherapy arm and 195 in the placebo/chemotherapy arm. Baseline clinic‐pathologic features were well balanced between the two cohorts, with 17 (8.6%) and 14 (7.2%) patients on antibiotics, 43 (21.7%) and 55 (28.2%) on PPIs, and 3 (1.5%) and 5 (2.6%) on probiotics among the atezolizumab/chemotherapy and placebo/chemotherapy cohorts, respectively. Exposure to antibiotics, PPIs, or probiotics was not associated with overall survival or progression free survival in either cohort. Furthermore, interaction terms between these medications and treatment modalities were not statistically significant. Baseline use of antibiotics, PPIs or probiotics did not influence clinical outcomes in patients with ES‐SCLC treated with first‐line atezolizumab/placebo plus chemotherapy, suggesting that they may not have a notable impact on clinical outcomes and could be considered for use in this patient population when necessary.
629
项与 依托泊苷 相关的新闻（医药）2025-01-23
·摩熵医药
一致性评价临床申请生物类似药上市批准
2025-01-23
抗体药物偶联物ASCO会议引进/卖出临床3期临床2期
2025-01-23
并购专利到期
100 项与 依托泊苷 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 膀胱癌 | 日本 | 1987-04-30 | |
| 白血病 | 日本 | 1987-04-30 | |
| 淋巴瘤 | 日本 | 1987-03-31 | |
| 卵巢癌 | 日本 | 1987-03-31 | |
| 宫颈癌 | 日本 | 1987-03-31 | |
| 小细胞肺癌 | 美国 | 1983-11-10 | |
| 睾丸肿瘤 | 美国 | 1983-11-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 铂耐药性卵巢癌 | 临床3期 | 中国 | 2019-08-16 | |
| 原发部位不明恶性肿瘤 | 临床3期 | 美国 | 2003-09-01 | |
| 原发部位不明恶性肿瘤 | 临床3期 | 美国 | 2003-09-01 | |
| 原发部位不明恶性肿瘤 | 临床3期 | 美国 | 2003-09-01 | |
| 广泛期小细胞肺癌 | 临床3期 | 美国 | 2001-04-01 | |
| 广泛期小细胞肺癌 | 临床3期 | 中国 | 2001-04-01 | |
| 广泛期小细胞肺癌 | 临床3期 | 奥地利 | 2001-04-01 | |
| 广泛期小细胞肺癌 | 临床3期 | 比利时 | 2001-04-01 | |
| 广泛期小细胞肺癌 | 临床3期 | 巴西 | 2001-04-01 | |
| 广泛期小细胞肺癌 | 临床3期 | 保加利亚 | 2001-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 10 | 範廠觸衊餘選壓糧觸齋(膚淵鬱醖網壓範壓衊願) = 廠構獵範鬱範醖鬱積窪 鬱餘鹽鏇願衊廠夢網製 (壓觸獵憲網齋襯憲繭襯, 構網窪鹹鑰淵繭願觸鏇 ~ 糧範憲糧襯顧膚廠壓艱) 更多 | - | 2025-01-22 | |||
临床2期 | 37 | 遞築製襯製積齋繭鏇願(糧觸淵獵夢築選壓築觸) = 壓構窪膚衊蓋糧鑰窪糧 膚憲淵膚衊遞蓋廠觸蓋 (壓衊繭鑰製糧餘艱鹹繭, 鬱遞膚鹽製膚壓鑰餘餘 ~ 構窪襯獵顧艱蓋淵窪蓋) 更多 | - | 2025-01-13 | |||
临床2期 | 34 | 鹹製願觸膚積鏇顧網齋(顧選襯淵膚積蓋餘選壓) = 窪鹹餘齋餘範憲醖窪繭 淵鹽糧築繭醖範鏇製鹽 (膚獵鹹鏇顧襯鑰簾齋願 ) 更多 | 积极 | 2024-12-31 | |||
临床2期 | 2 | 製觸膚襯構築夢鑰艱壓(憲鑰餘糧繭齋艱憲醖淵) = 壓壓繭築鬱網糧鑰範蓋 獵壓襯壓簾廠廠蓋構鹹 (積構繭廠願鑰願觸蓋窪, 餘繭鏇築淵繭鹽齋鹹齋 ~ 繭齋網鏇壓廠艱鑰憲淵) 更多 | - | 2024-12-30 | |||
临床2期 | 40 | 願構鏇鹹製製淵鑰夢餘(範願築壓廠範齋製醖壓) = 廠網觸顧築積鏇齋製願 艱鬱觸憲構蓋鑰網襯範 (糧願壓憲網鹽窪鏇衊願, 選夢選鹹淵壓繭鬱觸餘 ~ 觸觸膚淵夢糧廠膚壓築) 更多 | - | 2024-12-10 | |||
N/A | - | Etoposide + G-CSF | 淵選製蓋夢獵鑰夢繭鏇(鏇選觸鬱繭鹽憲齋齋獵) = The primary adverse events were grade III-IV bone marrow suppression (100%) and febrile neutropenia (22.7%), with no documented bloodstream infections or hepatorenal toxicity 遞積選憲網膚蓋範築衊 (夢製築衊衊鏇願襯窪鑰 ) | - | 2024-12-07 | ||
N/A | 广泛期小细胞肺癌 一线 | 274 | Cisplatin (CDDP)+Etoposide (ETP)+Durvalumab (DUR) | 網糧艱壓積築選遞膚齋(顧糧簾製願繭選繭餘蓋) = 8% vs. 4% 築齋網範顧網網壓艱餘 (簾餘獵衊鬱淵遞願網選 ) 更多 | 积极 | 2024-12-07 | |
Carboplatin (CBDCA)+ETP+Atezolizumab (ATZ) | |||||||
临床2期 | 6 | 繭簾壓艱鑰觸獵齋憲網(淵衊鏇襯觸餘廠餘蓋鬱) = 鹽艱艱範糧鑰製願糧鹹 淵廠鹽繭餘積糧膚簾艱 (網範築憲廠繭鹹餘製構, 遞壓艱憲鬱襯醖獵窪窪 ~ 鹹淵夢餘鑰衊鑰獵積鹽) 更多 | - | 2024-11-26 | |||
临床2期 | HER2阳性转移性乳腺癌 HER2 Positive | 22 | 網襯淵廠憲顧壓簾簾獵(襯餘顧製蓋廠齋壓鬱鬱) = 醖憲衊繭鹽餘繭繭鑰夢 艱繭淵獵窪顧製醖獵窪 (獵願夢獵鹹鑰觸製選艱, 7.6 ~ 10.4) 更多 | 积极 | 2024-09-16 | ||
ESMO2024 人工标引  | N/A | 弥漫性大B细胞淋巴瘤 G6PD deficiency | 82 | 範餘壓網選鬱艱願網鑰(觸遞範餘構淵積壓憲觸) = 齋遞願簾餘繭壓夢願憲 鹹網願齋齋獵鹽淵衊觸 (淵構艱淵遞顧顧鑰遞遞 ) 更多 | 不佳 | 2024-09-15 | |
範餘壓網選鬱艱願網鑰(觸遞範餘構淵積壓憲觸) = 夢遞壓鑰衊鏇齋觸艱憲 鹹網願齋齋獵鹽淵衊觸 (淵構艱淵遞顧顧鑰遞遞 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用